6-KThe Wire
GSK plc files 6-K
Filed Apr 27, 2026 · 2mo ago · Accession 0001654954-26-003947
Plain English
GSK's investigational liver therapy, efimosfermin, has received US FDA Breakthrough Therapy and EMA PRIME designations for MASH, reflecting its potential to address a significant unmet medical need. Phase II data showed efimosfermin improved liver fibrosis in MASH patients.
Filing details
- Company
- GSK plc
- Ticker
- GSK
- CIK
- 1131399
- Form type
- 6-K
- Filing date
- Apr 27, 2026
- Report date
- Apr 27, 2026
- Document
- a0447c.htm
- Size
- 43 KB